MONTREAL and CHARLOTTE, N.C. , July 31, 2024 (GLOBE NEWSWIRE) — Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto , will participate in the BTIG Virtual Biotechnology Conference , to take place from August 5-6, 2024 .
Related Posts
-
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
-
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
